New health care policy changes will soon affect weight-loss drugs
Novo Nordisk (NVO) and Eli Lilly (LLY) manufacture the top three weight loss drugs on the market, but heightened demand is ...
pharmaphorum10y
Safety warnings will hold back new obesity treatment Contrave
Contrave (naltrexone HCI and bupropion HCI) extended-release tablets have been approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in ...